Anti-Ferroptotic Treatment Deteriorates Myocardial Infarction by Inhibiting Angiogenesis and Altering Immune...

Area of Science:

• Cardiology
• Cell Biology
• Regenerative Medicine

Background:

• Mammalian heart regeneration is limited, with cardiac diseases causing cardiomyocyte loss via regulated cell death (RCD).
• Ferroptosis, an iron-dependent RCD, is identified as a primary mechanism of cardiomyocyte death in injured hearts.
• Understanding RCD mechanisms is vital for developing heart regeneration therapies.

Purpose of the Study:

• To investigate the underlying mechanisms of ferroptosis preference in cardiomyocytes.
• To evaluate the therapeutic potential of inhibiting ferroptosis in cardiac injury models.

Main Methods:

• Administration of anti-ferroptotic reagents to infarcted mouse hearts.
• Assessment of neonatal heart regeneration and juvenile cardiac function.
• Analysis of immune and angiogenic responses in regenerating mouse hearts.

Main Results:

• Anti-ferroptotic treatment did not enhance neonatal heart regeneration and worsened juvenile cardiac function.
• Ferroptotic cardiomyocytes were found to support wound healing by secreting pro-angiogenic factors.
• Inhibition of ferroptosis altered immune and angiogenic responses in the regenerating heart.

Conclusions:

• Cardiomyocytes exhibit a preference for ferroptosis, which plays a beneficial role in cardiac wound healing.
• Targeting ferroptosis requires careful consideration, as its inhibition can be detrimental to cardiac function and regeneration.
• Findings offer insights for designing effective anti-cell-death therapies for heart disease, emphasizing the nuanced role of ferroptosis.